February - 2023

NEWS

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints New Chief Operating Officer

Ymmunobio Accepted into Innosuisse Core Coaching

Dr. Katrin Rupalla Interviewed by Global Business Reports

Drug Discovery & Development

Fierce Biotech: Appointment of Michel Janicot

FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer

Ymmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...

Ymmunobio Appoints Dr. Caroline Germa to Board of Directors

Medical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...

Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer

Growing preclinical-stage biotech company adds to executive team RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical...